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Results
Costimulatory Requirement of CTL Responses
Summary Depends on Properties of the Virus
As reported earlier, lymphocytic choriomeningitis vi-
Current models suggest that T cells that receive only rus (LCMV) infection of CD28-deficient (CD282/2) and
signal-1 through antigenic stimulation of the T cell CD281/1 mice generates comparable cytotoxic T lym-
receptor (TCR) become anergic, but will mount an im- phocyte (CTL) activity against LCMV–glycoprotein
mune response when a costimulatory signal-2 is pro- (LCMV–gp) (Figure 1A) (Shahinian et al., 1993), which
vided. Using mice deficient for an important costimula- contains the dominant class I MHC-presented epitope
tory molecule, CD28, we show that a transient signal-1 in H-2b mice (Pircher et al., 1990). This CTL response
alone, either through infection with an abortively repli- was fully efficient, since it eliminated LCMV with normal
cating virus, or through injection of viral peptide, aner- kinetics (data not shown) and conferred immunological
gizes CD81 T cells, demonstrating the biological rele- protection by rendering mice resistant against subse-
vance of T cell anergy in vivo. However, in the absence quent challenge infection with vaccinia–LCMV–gp re-
of CD28, continued presence of signal-1 alone, either combinant virus (vv–LCMV–gp) (Figure 1B); such resis-
through prolonged viral replication or repeated injec- tance is mediated exclusively by CD81 CTL (Binder and
tion of peptide, prevents the induction of anergy and Ku¨ndig, 1991). Antigenic restimulation of spleen cells
generates a functional T cell response in vivo. from LCMV-infected CD282/2 mice readily generated cy-
totoxicity, without adding exogenous cytokines (Figures
1C and 1D). Limiting dilution analysis confirmed that
Introduction massive in vivo proliferation of LCMV–gp-specific CD81
T cells occurred in CD282/2 mice, since frequencies rose
In vitro, several models demonstrate that the generation from <1026 to 1/50 (Figure 1E). Taken together, in
of maximal T cell responses requires not only signal-1 CD282/2 mice LCMV infection generated cytotoxic T cell
through the T cell receptor (TCR), but also a costimula- activity and the in vivo proliferation of specific CD81 T
tory signal-2 (Schwartz, 1990). The interaction of CD28 cells was not impaired.
on T cells with B7 family molecules on antigen-pre- This CD28 independence did not correlate with a par-
senting cells is important for providing signal-2, since ticular LCMV epitope, since LCMV infection of CD282/2
it up-regulates interleukin-2 (IL-2) production and T cell mice induced normal CTL responses not only against
proliferation (June et al., 1994; Allison, 1994; Linsley and the immunodominant glycoprotein–epitope, but also
Ledbetter, 1993; Schwartz, 1992).Stimulation of the TCR against minor epitopes such as the nucleoprotein of
in the absence of signal-2 has been shown to induce T LCMV in H-2b mice (Hany et al., 1989). This is demon-
cell anergy, a state characterized by unresponsiveness strated by the finding that CD282/2 mice immunized with
to further antigenic stimulation, which may be reversed LCMV are resistant not only to subsequent challenge
by exogenous IL-2 (Schwartz, 1990; Bluestone, 1995). infection with vv–LCMV–gp, but also to vaccinia–LCMV–
In vivo, this two signal model of lymphocyte activation nucleoprotein recombinant virus (vv–LCMV–np) (Figures
is controversial. Although aberrant expression of co- 2A and 2B). Furthermore, in CD282/2 H-2k mice, the im-
stimulatory molecules or cytokines can enhance T cell munopathological footpad swelling reaction after local
activation (Guerder et al., 1994; Harlan et al., 1994; Heath infection with LCMV was unaltered (Figure 2C), demon-
et al., 1992; Chen et al., 1992; Townsend and Allison, strating that CD81 CTL responses against LCMV in H-2k
1993; Baskar et al., 1994; Fearon et al., 1990; Gans- mice were fully efficient, despite the fact that H-2k mice
bacher et al., 1990), the absence of CD28, B7-1, or IL-2 are CTL low responders against LCMV (Hany et al.,
does not appear to impair the immune response to cer- 1989). Thus, the CD28 independence of the CTL re-
tain antigens in vivo (Shahinian et al., 1993; Ku¨ndig et al., sponse induced by LCMV infection does not correlate
1993c; Bluestone, 1995; Freeman et al., 1993). Notably, with any particular viral epitope, but is a property inher-
ent to the virus itself.CD81 T cells seem less dependent on costimulation than
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Figure 1. Costimulatory Requirement of CTL Responses Depends on the Virus
(A–E) LCMV infection: Mice were infected intravenously with LCMV (2,000 pfu) and the LCMV–gp-specific immune response was assessed
after 8 days. (A) Primary ex vivo CTL activity measured by 51Cr release assays. (B) Antiviral protection assessed by challenge infection with
a vaccinia–LCMV–gp recombinant virus (vv–LCMV–gp): LCMV-immunized mice were challenged intracerebrally with vv–LCMV–gp and titers
of this virus were measured in brains 5 days after the challenge infection. (C) Spleen cells were stimulated in vitro with LCMV-infected peritoneal
macrophages, without adding ConA supernatant (CAS), or in the presence of CAS (D). The indicated dilutions of responder cultures were
tested for specific cytotoxicity on LCMV-infected target cells. (E) Limiting dilution analysis for LCMV–gp-specific CTL precursor cells in the
presence of CAS.
(F–J) VSV infection: Mice were infected intravenously with VSV and VSV–np-specific CD81 T cell responses were assessed after 6 days. (F)
Primary ex vivo CTL activity. (G) Antiviral protection assay using a vaccinia-VSV–np recombinant virus (vv–VSV–np) for challenge infection.
(H) Spleen cells were stimulated in vitro with VSV-infected splenic macrophages (Ku¨ndig et al., 1993a), without adding CAS, or in the presence
of CAS (I). The indicated dilutions of responder cultures were tested for specific cytotoxicity on VSV-infected target cells. (J) Limiting dilution
analysis for VSV–np-specific CTL precursor cells, in the presence of CAS. Closed triangles, CD282/2; open triangles, CD281/1; open circles,
CD281/1 that had been depleted in vivo of CD41 T cells before the priming infection (Cobbold et al., 1984); open diamonds, noninfected
CD281/1 control mice. All mice are H-2b/b with more than 6 backcrossings into C57BL/6.
In contrast, infection of CD282/2 mice with vesicular specific CD81 T cells and these CD81 T cells proliferated
minimally, followed by unresponsiveness to further anti-stomatitis virus (VSV) did not induce any directly mea-
surable CTL activity in vitro (see Figure 1F). Induction of genic stimulation in vivo and in vitro, unless exogenous
cytokines were added.strong CTL activity after VSV infection in CD4-depleted
mice indicated that the lack of CTL response in the
absence of CD28 was not due to impaired T help (see Requirement for CD28 Costimulation Inversely
Correlates with Viral ReplicationFigure 1F). In vivo, VSV-immunized CD282/2 mice were
not resistant against challenge infection with vaccinia– How can this discrepancy between LCMV and VSV be
explained? There are several differences between LCMVVSV recombinant virus expressing VSV–nucleoprotein
(np), containing the dominant CTL epitope against VSV and VSV. A very striking difference is the extent and
duration of viral replication in the host. LCMV is a naturalin H-2b mice (Puddington et al., 1986; Ku¨ndig et al.,
1993b) (see Figure 1G). However, using spleen cells from mouse pathogen and after intravenous infection repli-
cates widely and extensively in several mouse organsVSV-infected mice, in vitro restimulation with antigen
could generate VSV–np-specific CTL activity, but only (Lehmann-Grube, 1971; Buchmeier et al., 1980). In the
spleen, infectious virus can be recovered at any time-if exogenous cytokines were added (see Figures 1H and
1I). Such in vitro stimulation does not generate cytotox- point from day 1 through days 8–10 after infection. On
day 4–5, high maximal titers around 106 pfu per gramicity in unprimed mice, thus indicating that VSV infection
of CD282/2 mice was not simply a null event for specific spleen are reached. In contrast, VSV is not a natural
mouse pathogen, and after intravenous infection repli-CD81 T cells, but that these T cells had been activated.
In fact, limiting dilution analysis for VSV–np-specific cates poorly in the spleen, where only low titers of live
virus (10–100 pfu per gram spleen) can be recoveredCD81 T cells, which is performed in the presence of
exogenous cytokines, revealed that proliferation had after 1 day, but not 2 days after infection (Wagner, 1987).
Thus, compared with VSV, live LCMV titers are aroundtaken place in vivo: frequencies rose from <1/106 in unin-
fected mice up to1/50,000 (see Figure 1J). This prolifera- 104–105 times higher and live LCMV can be recovered
roughly 10 times longer. Thus, LCMV peptide will betion was, however, 50–100 times less than in CD281/1
mice. These data demonstrate that VSV infection primed presented in higher doses and for a longer duration.
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which replicates in lymphatic organs of the mouse only
abortively, were CD28 dependent (Figure 2E).
In CD282/2 mice infected with low virulence vaccinia
virus expressing recombinant VSV–np, in vitro restimula-
tion assays revealed that CD81 T cells specific for this
defined antigen mounted a weak but significant re-
sponse (Figure 2F), also in absence of exogenous cyto-
kines. Addition of exogenous IL-2, however, was neces-
sary to increase in vitro responsiveness (Figure 2G).
Thus, presentation of VSV–np to the immune system in
the form of the vaccinia recombinant virus, instead of
VSV wild type, could induce a weak CD81 T cell re-
sponse, which became detectable only after in vitro
restimulation, but not by direct ex vivo measurement of
CTL activity. This in vitro response was significantly, but
not absolutely, dependent on exogenous cytokines. The
low virulence vaccinia virus strain used here may mea-
surably replicate in certain mouse organs (Binder and
Ku¨ndig, 1991; Karupiah et al., 1990) and may therefore
be considered more virulent than VSV wild type. These
data confirm that virulence appears to be the parameter
determining T cell responsiveness in absence of CD28.
Using these viruses, a correlation between viral repli-
Figure 2. The Requirement for CD28 Depends Upon the Virulence cation and CD28 dependence could be made and further
of the Pathogen and Not Properties Associated with the Viral Epitope experiments were done to examine whether the higher
or Haplotype
antigen dose or the continued presence of antigen
(A–C) CTL responses against several LCMV epitopes are CD28 inde- could render the T cell response independent of CD28.
pendent. (A and B) H-2b/b mice depleted of CD41 T cells were immu-
We therefore immunized CD282/2 TCR-transgenic micenized intravenously with LCMV and, after 12 days, challenged intra-
(TCR1) specific for LCMV–gp (Pircher et al., 1989) withcerebrally with (A) vv–LCMV–gp or (B) vv–LCMV–np. Vaccinia virus
titers in brains were determined 5 days after challenge infection. the dominant LCMV–gp peptide (amino acids 33–41),
Closed triangles, CD282/2 mice; open circles, CD281/1 mice; open and varied either the peptide dose or the duration of
diamonds, unprimed CD281/1 mice. (C) H-2k/k mice depleted of CD41 antigen presentation by continued peptide injections.
T cells were infected with LCMV infection into their hind footpad. In all the following experiments, peptide was injected in
Closed triangles, CD282/2 mice; open circles, CD281/1 mice.
saline to limit the duration of peptide presentation in(D–E) Vaccinia virus virulence determines CD28 dependence. Mice
vivo (Widmann et al., 1991; Ku¨ndig et al., 1992).were infected with vaccinia virus and primary ex vivo CTL activity
was tested on vaccinia virus infected target cells. (D) infection with
highly virulent vaccinia virus strain (WR); (E) infection with low viru-
CD28 Deficiency Does Not Alter Antigenlence vaccinia virus strain (thymidine kinase negative). Spontaneous
Dose Required for T Cell Activation51Cr-release was <20% and nonspecific lysis of uninfected control
target cells was <18% for all effectors. Closed triangles, CD282/2; The importance of the dose was evaluated by injecting
open triangles, CD281/1; open circles, CD281/1 that had been de- TCR1 mice with different amounts of LCMV–gp peptide.
pleted in vivo of CD41 T cells before the priming infection (Cobbold Blast formation of CD81 T cells, which increases the
et al., 1984); open diamonds, noninfected CD281/1 control mice. forward scatter in FCM analysis, was taken as a marker(F–G) Infection of CD282/2 mice with vv–VSV–np partially anergizes
of transgenic T cell activation. Single parameter FCMCD81 T cells. CD282/2 (closed triangles) and CD281/1 mice (open
analyses are shown, since roughly 80%–95% of all CD81triangles) were infected with the low virulence vaccinia virus strain
vv–VSV–np. After 6 days, spleen cells were restimulated in vitro T cells express the transgenic receptor, and this per-
using VSV-infected splenic macrophages (Ku¨ndig et al., 1993a), ei- centage even increases after specific immunization. In
ther without (F) or with (G) ConA supernatant. The indicated dilution both TCR1 CD282/2 and TCR1 CD281/1 mice, the dose
of responder cultures were tested for specific cytotoxicity on required for CD81 T cell blast formation, occurring within
VSV–np-transfected syngeneic target cells (Puddington et al., 1986).
24 hr after peptide injection, was 0.01–0.1 mg (FiguresOpen diamonds represent unprimed CD281/1 control mice restimu-
3A and 3B).lated with the same protocol.
The following experiment was designed to confirm Peptide Induces Unresponsiveness
of CD282/2 T Cellsthat viral replication per se, and not other differences
between viruses, can explain the observed difference In both TCR1 CD282/2 and TCR1 CD281/1 mice, 3 days
after peptide injection, CD81 T cell blasts were no longerin CD28 dependence. Two vaccinia virus strains were
used to infect CD281/1 and CD282/2 mice. These vaccinia detectable by FCM analysis, regardless of the peptide
dose injected (data not shown). The CD81 T cell popula-virus strains are identical except for one gene coding
for the virulence factor thymidine kinase (Buller et al., tion had been expanded comparably in both groups
(data not shown; similar to Figures 4A–4F below). How-1985): CTL responses against the highly virulent strain,
which replicates in lymphatic organs of the mouse for ever, peptide-primed TCR1 CD282/2 CD81 T cells no
longer responded to antigenic stimulation invitro, unlessseveral days, were CD28 independent (Figure 2D),
whereas CTL responses against the low virulence stain, exogenous cytokines were added (Figures 3C and 3D),
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Figure 3. Induction of T Cell Unresponsiveness by Injection with LCMV–Peptide
(A–B) CD28 deficiency does not alter the antigen dose required for T cell activation. (A) TCR1 CD281/1 and (B) TCR1 CD282/2 mice were
intravenously injected with the indicated doses of LCMV–gp peptide (amino acids 33–42). After 24 hr, the forward scatter, correlating to cell
size, of CD81 T cells was analyzed by FCM.
(C–D) After peptide injection, TCR1 CD282/2 CD81 T cells no longer generate cytotoxicity in vitro. (C) TCR1 CD281/1 and (D) TCR1 CD282/2
mice were intravenously injected with the indicated doses of LCMV–gp peptide. After 3 days, mice were sacrificed and spleen cells in vitro
stimulated with the same peptide. The in vitro generation of LCMV–gp-specific cytotoxicity was tested on LCMV–gp peptide-labeled target
cells, at the indicated dilution of the responder cultures. Open triangles, restimulation in absence of CAS; closed triangles, restimulation in
presence of CAS. Spontaneous release was <24% and nonspecific lysis of control target cells (not labeled with viral peptide) was <20% for
all effectors.
(E–F) After peptide injection, TCR1 CD282/2 CD81 T cells no longer proliferate in vitro. (E) TCR1 CD281/1 and (F) TCR1 CD282/2 mice were
intravenously injected with LCMV–gp peptide. After 3 days, mice were sacrificed and spleen cells in vitro stimulated with the same peptide
(left two columns) or mediawithout peptide (right two columns). T cell proliferationwas assessed by determination of [3H]thymidine incorporation.
Open bars, [3H]thymidine uptake without CAS in cultures. Closed bars, [3H]thymidine uptake with CAS.
whereas such antigenic stimulation of unprimed CD81 CD81 T cells also did not proliferate in vitro, unless
exogenous cytokines were added (Figures 3E and 3F),T cells in TCR1 CD282/2 mice readily generated cytotox-
icity without exogenous cytokines. Corresponding to whereas naive TCR1 CD282/2 T cells proliferated nor-
mally, at least during the first 2 days. (At later timepoints,the lack of cytotoxicity, peptide-primed TCR1 CD282/2
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Figure 4. Analysis of Activation, Peripheral
Expansion, and Deletion in the Absence of
CD28
(A–F) Adult thymectomized TCR1 CD281/1 (A)
and TCR1 CD282/2 (B) mice were intrave-
nously injected with the indicated LCMV–gp
peptide doses. Percentage of CD81 T cells
was measured among peripheral blood leu-
kocytes (6SD, n 5 5 per group).
(G–L) Phenotypic analysis of CD81 T cell
blasts. FCM analysis for surface expression
of CD69 (G, J), or IL-2Ra (H, K) 1 day after
peptide injection and for surface expression
of the transgenic TCR (Vb8) (I, L) 3 days after
peptide injection are shown. Profiles of pep-
tide-induced CD81 T cell blasts are marked
“pep” and compared with profiles of CD81 T
cells of unprimed mice (unmarked).
similar to an earlier report on allo-specific proliferation CD81 T cells, whereas injection of 1 mg and 0.1 mg, which
readily induced T cell unresponsiveness (see Figure 3),[Green et al., 1994, Kawai et al., 1996], we found reduced
proliferation also in unprimed CD282/2 mice.) did not lead to deletion. In TCR1 CD281/1 mice, injection
with 10 mg similarly deleted roughly half of the CD81 TThus, these data confirm the inverse correlation of
pathogen replication with the CD28 requirement within cells, but evidence of deletion was also seen in TCR1
CD281/1 mice injected with only 1 mg and 0.1 mg. Takenthe LCMV system. Immunization of CD282/2 mice with
a nonreplicating LCMV antigen, such as LCMV peptide, together, the observed T cell unresponsiveness did not
correlate with T cell deletion. In contrast, CD28 defi-induced T cell unresponsiveness, whereas immuniza-
tion with LCMV virus induced normal CTL responses. ciency rather protected T cells from deletion. Interest-
ingly, more than 3 weeks after peptide injection, in thy-The unresponsiveness induced by LCMV peptide was
reversible by the presence of exogenous cytokines, sim- mectomized mice, T cells could again be restimulated
in vitro, even in the absence of exogenous cytokines,ilar to the unresponsiveness induced after VSV infection.
It is important to note here that this unresponsiveness indicating T cell unresponsiveness in TCR1 CD282/2 mice
was transient (data not shown).was not overcome even when mice were injected with
high antigen doses, such as 100 mg of peptide.
T Cell Unresponsiveness Is Biologically
Significant During Viral Challenge In VivoT Cell Unresponsiveness Does Not
Correlate with T Cell Deletion We next examined, whether the peptide-induced T cell
unresponsiveness observed in vitro in TCR1 CD282/2The use of the transgenic mouse system allowed us to
analyze the fate of T cells rendered unresponsive by mice, i.e., the need for exogenous IL-2, was significant
during viral challenge infection in vivo. TCR1 CD281/1antigen contact. Adult thymectomized TCR1 CD282/2
and TCR1 CD281/1 mice were injected with different pep- and TCR1 CD282/2 mice were injected with peptide and
after 3 days challenged with a vv–LCMV–gp recombi-tide doses. In both groups, the CD81 T cell population
first expanded comparably for all three peptide doses nant virus (Bachmannand Ku¨ndig,1994). While the CD81
T cells from CD281/1 mice could control viral replication,used (10 mg, 1 mg, 0.1 mg) (Figure 4). The CD81 T cell
population reached a maximum on day 3, followed by CD282/2 mice could not (Figure 5), and visibly suc-
cumbed to disease. Together with the results from VSV-a rapid decline on day 4. In TCR1 CD282/2 mice, injection
with 10 mg was followed by deletion of roughly half the infected CD282/2 mice, which also were not protected
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activation markers, such as CD69 and IL-2Ra (see Fig-
ures 4G, 4H, 4J, and 4K), as well as CD44 and the trans-
ferrin receptor (data not shown), were expressed at
markedly lower levels in TCR1 CD282/2 mice. However,
the T cell unresponsiveness observed in CD282/2 mice 3
days after peptide injection did not correlate with down-
regulation of the TCR (see Figures 4I and 4L), since this
event was less pronounced in TCR1 CD282/2 mice, than
in TCR1 CD281/1 mice.
Short-Lived CTL Response in CD282/2 Mice
We next assessed whether the CD81 T cell blasts in
CD282/2 mice observed 24 hr after peptide injection,
although expressing reduced levels of activation mark-
ers, possessed cytotoxic function. Interestingly, they
exhibited normal CTL activity when tested directly ex
vivo (Figure 6A). When such peptide-primed TCR1
CD282/2 mice were immediately challenged with vv–
LCMV–gp recombinant virus, they remained healthy and
Figure 5. T Cell Unresponsive to Viral Challenge In Vivo. no viral replication could be measured, whereas un-
Antiviral protection was assessed 3 days after injection with 10 mg primed controlmice succumed tovv–LCMV–gp-induced
of LCMV–gp peptide by challenge infection with vv–LCMV–gp either disease (data not shown).This was expected, since such
intracerebrally or intraperitoneally. Titers of vv–LCMV–gp were mea- in vivo assessment of CTL activity is more sensitive than
sured in brains orovaries 5 days after the challenge infection. Closed
the direct ex vivo measurement of CTL activity usingtriangles, CD282/2; open triangles, CD281/1 mice.
51Cr release assays (Bachmann and Ku¨ndig, 1994). Fur-
thermore, at this early timepoint, in vitro antigenic stimu-
lation generated specific cytotoxicity (Figures 6B and
against subsequent challenge infection with a vv–VSV– 6C) and proliferation (data not shown) of CD81 T cells
np recombinant virus in vivo, these studies demonstrate even in the absence of exogenous cytokines.
the biological relevance of the CD81 T cell unrespon- In contrast, 3 days after peptide injection, when CD81
siveness observed in vitro. T cells were unresponsive in vitro (similar to Figure 3;
data not shown), CTL activity was completely absent in
T Cell Unresponsiveness Does Not Correlate TCR1 CD282/2 mice (Figure 6D). At this timepoint, TCR1
with Down-Regulation of the TCR CD281/1 mice still exhibited ex vivo CTL activity and
Phenotypic comparison of transgenic CD81 T cell blasts normal in vitro reactivity (data not shown; similar to Fig-
ures 3C and 3E). Taken together, very early after antigen24 hr after peptide injection revealed that early T cell
Figure 6. Peptide Injection Induces Short-Lived CTL Response in TCR1 CD282/2 Mice
(A–C) CD81 T cell response 1 day after peptide injection. (A) Ex vivo CTL activity on targets labeled with LCMV–gp peptide. (B) spleen cells
were in vitro stimulated with LCMV–gp peptide and the generation of cytotoxicity was assessed on LCMV–gp peptide-labeled target cells, at
the indicated dilutions of responder cultures. No CAS was added to cultures. (C) CAS was present in cultures.
(D) CD81 T cell response 3 days after peptide injection: ex vivo CTL activity on H-2b targets labeled with LCMV–gp peptide. In all 51Cr release
assays shown spontaneous release was <26% and nonspecific lysis of uninfected control target cells was <21% for all effectors. All animals
used were TCR1 mice. Closed triangles, peptide-primed CD282/2 mice; open triangles, peptide-primed CD281/1 mice; closed diamonds,
unprimed CD282/2 mice; open diamonds, unprimed CD281/1 mice. Circles, unprimed CD282/2 (open circles) or unprimed CD281/1 (closed
circles) mice tested on control targets without peptide.
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Figure 7. Prolonged Signal-1 Makes CTL Response CD28 Independent
(A–B) Mice were intravenously injected with 1 mg of peptide every 12 hr (7 injections) or left unprimed. LCMV–gp-specific CTL activity was
measured 12 hr after the last peptide injection in spleens by a primary ex vivo 51Cr release assay (A). Forward scatter of these CD81 T cells,
peptide-primed as well as unprimed TCR1 CD282/2 and TCR1 CD281/1, are virtually identical in size so that curves overlap (B).
(C–D) Mice were intravenously injected with 1 mg of peptide every 12 hr (7 injections) or left unprimed. These mice were tested in the same
assay, but the time interval after the last peptide injection was 24 hr. (C) Forward scatter of CD81 T cells is shown (D) as in (B). In all 51Cr
release assays shown, target cells have been prepulsed with the LCMV–gp peptide. Spontaneous release was <17% and nonspecific lysis
of uninfected control target cells was <22% for all effectors. All animals used were TCR1 mice. Closed triangles, peptide-primed CD282/2
mice; open triangles, peptide-primed CD281/1 mice; closed diamonds, unprimed CD282/2 mice; open diamonds, unprimed CD281/1 mice.
contact CD81 T cells in TCR1 CD282/2 mice were func- which might not have been primed and therefore re-
mained naive, nor was it due to naive new thymic emi-tional, exhibiting efficient cytotoxicity, and these T cells
could be normally restimulated in vitro. However, this grants, which would then be freshly activated with every
additional peptide injection. First, CTL activitywas main-response was not sustained and followed by T cell unre-
sponsiveness. tained only if peptide was injected every 12 hr, but not
by injection every 24 hr (data not shown). If the response
was due to naive cells, then prolongation of the timeProlonged Signal-1 Makes T Cell
Responses CD28 Independent interval between injections would allow for more naive
cells to accumulate and should therefore increase theSince high antigen doses could not overcome the CD28
requirement of the CTL response (see Figure 3), we response. Second, 3 days after a single peptide injec-
tion, secondary in vitro restimulation with antigen in bulkevaluated whether the duration of signal-1 determined
CTL responsiveness in CD282/2 mice. Note that in all cultures did not generate cytotoxicity (see Figure 3).
Such bulk culture restimulation is highly sensitive andabove experiments transgenic mice received only a sin-
gle injection of viral peptide without adjuvant, so that detects specific CD81 T cells at frequencies down to
1026 (Bachmann and Ku¨ndig, 1994). Thus, naive cellsthe peptide has a very short half-life in vivo (Widmann
et al., 1991; Ku¨ndig et al., 1992). must be at frequencies lower than that, which is far
below the detection level of the primary ex vivo cytotox-As shown in Figure 3, injection with 1 mg of viral pep-
tide activates all transgenic CD81 T cells in the spleen. icity assays performed in this set of experiments. To
detect primary ex vivo cytotoxicity, specific CD81 T cellsIn TCR1 CD282/2 mice, CD81 T cells then become unre-
sponsive within 3 days. During these 3 days, if TCR1 have to be at frequencies of >1023. Third, after 3 days
of repeated peptide injections, FCM analysis showed aCD282/2 mice were continuously injected with additional
peptide (1 mg every 12 hr), high levels of CTL activity, markedly larger CD81 T cell population in the spleen
than after a single peptide injection (data not shown),which could be measured directly ex vivo, were main-
tained (Figure 7A). In a similar series of experiments, we again indicating that the same population of CD81 T
cells isbeing further restimulated with additionalpeptideconfirmed that mice injected with peptide repeatedly
were resistant to challenge infection with vv–LCMV–gp injections.
However, already 24 hr after withdrawal of this contin-(data not shown). This sustained CTL activity measured
on day 3 after repeated peptide injections was due to ued signal-1, CTL activity completely collapsed in TCR1
CD282/2 mice, while remaining readily detectable incontinued restimulation of the same CD81 T cell popula-
tion and not due to a small fraction of CD81 T cells, TCR1 CD281/1 mice (Figure 7C), although in both TCR1
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CD282/2 and TCR1 CD281/1 mice, CD81 T cells were still detectable immune function, followed by minimal dele-
tion and anergy. A weak activation may lead to detect-blasts (Figure 7D). Thus, in contrast with a single high
dose injection of viral peptide, repeated injections with able phenotypic activation, a smaller “window” of im-
mune function, undetectable expansion and deletion,low doses could mimic extensive viral replication and
overcome the CD28 requirement. However, T cell re- but once functional anergy has been established, it will
persist in a manner that reflects persistence of antigen.sponses were maintained only as long as signal-1 was
provided. In this report, we show that the phenotype of T cell
activation is influenced by CD28-mediated costimula-
tion invivo. In absence of CD28, T cellactivation markersDiscussion
are reduced, CD81 T cell blasts exhibit measurable cyto-
toxic activity only for a short period of time, T cell dele-Our data demonstrate that infection of CD282/2 mice
with pathogens that do not replicate extensively, such tion is less marked, and T cell anergy is observed at
an early timepoint. Thus, in the absence of CD28, theas VSV (Wagner, 1987) or low virulence vaccinia virus
(Buller et al., 1985), or a single injection of TCR1 CD282/2 induction of peripheral tolerance may be biased toward
anergy, since normal T cell activation signal is alteredmice with short-lived viral peptides (Ku¨ndig et al., 1992;
Widmann et al., 1991), initially induced T cells. VSV- in these animals.
These studies analyzed the CD28 requirement for thespecific CD81 T cells were primed and minimal prolifera-
tion was observed in vivo. Similarly, peptide injection in vivo generation of CD81 T cell–mediated cytotoxicity
against a variety of antigens that differ in their kineticsin vivo induced CD81 T cell blasts exhibiting cytotoxic
effector function and expanded the CD81 transgenic T and extent of antigen presentation in the host. After
intravenous infection of mice with VSV or with the lowcell population. However, this initial T cell response was
transient and followed by T cell unresponsiveness in virulence vaccinia virus strain, low titers of live virus can
be recovered from spleen for only 1 or 2 days (Wagner,vitro and in vivo, which could be reversed by exogenous
cytokines. 1987; Buller et al., 1985). In contrast with high virulence
vaccinia virus (Buller et al., 1985) and LCMV (Lehmann-Antigen-induced unresponsiveness of mature periph-
eral T cells may be due to several mechanisms: clonal Grube, 1971; Buchmeier et al., 1980), higher virus titers
can be recovered for a prolonged period of time, e.g.,deletion or exhaustion, down-regulation of the TCR, or
anergy (Zinkernagel et al., 1993; Kisielow et al., 1991; very high LCMV titers are recovered around day 4, and
LCMV can be detected in the spleen for 8–10 days. TheHa¨mmerling et al., 1993; MacDonald et al., 1993; Mar-
rack et al., 1993; Sprent et al., 1993; Rammensee et al., CD28 dependence of the CD81 T cell response inversely
correlated with the virulence of the above viruses; in1989; Ramsdell and Fowlkes, 1990). Given high doses
of viral peptide, TCR1 CD281/1 and TCR1 CD282/2 mice the absence of CD28, infection with VSV and the low
virulence vaccinia virus did not generate cytotoxicity,showed clonal expansion followed by down-regulation
of the TCR T cell deletion, possibly due to exhaustion. whereas infection with the high virulence vaccinia virus
or with LCMV generated normal cytotoxicity.However, both the first and second mechanisms could
not explain the unresponsiveness observed in CD28- We further dissected whether the extent of viral repli-
cation, i.e., the antigen dose, or duration of viral replica-deficient mice, since both events were even more pro-
nounced in CD281/1 mice, which still retained antiviral tion, i.e., the duration of antigen presentation, rendered
the CD81 T cell response CD28 independent. Analysiseffector function. The unresponsiveness observed here
was induced only in absence of CD28-mediated costi- using TCR1 CD281/1 and TCR1 CD282/2 mice showed
that a 104-fold increase of the specific virus peptide dosemulation and could be reversed by exogenous IL-2. It
thus fits the in vitro characteristics of the third mecha- could not mimic viral replication (Figure 3). However,
repeated injections of low peptide doses could sustainnism, anergy (Schwartz, 1990).
Interestingly, after injection with high doses of peptide the CTL response for the duration that peptide was given
(Figure 7). The use of viral peptides demonstrated thatseveral of the above tolerance mechanisms were ob-
served in CD282/2 mice, but after injection with lower sustained antigen presentation, rather than the high
dose of antigen, rendered the T cell response indepen-doses anergy could occur by itself: e.g., injection with
0.1 mg of peptide induced blast formation of all specific dent of CD28.
However, while differences in the duration of viral rep-T cells followed by anergy, but only minimal clonal
expansion without deletion or down-regulation of the lication may sufficiently explain the differential CD28
dependence observed, this may not be theonly explana-TCR (data not shown). Also, the observed T cell anergy
was of only transient nature, as reported for other situa- tion for the CD28 independence of the CD81 T cell re-
sponse against LCMV. It is quite possible that additionaltions where the antigen does not persist (Rocha et al.,
1993; Migita and Ochi, 1993; Ramsdell and Fowlkes, factors, such as the inductionof costimulatory pathways
other than via CD28, enhance T cell responsiveness1992).
This and other studies (reviewed by Sprent and Webb, against LCMV.
Our demonstration that the duration of signal-1 deter-1995) examining peripheral tolerance suggest that the
degree of T cell activation influences the outcome of mines the costimulatory requirement for T cells may
reconcile the controversy surrounding the two-signaltolerance induction. A strong activation signal will lead
to significant expansion, detectable immune function, model of lymphocyte activation in vivo (Bluestone,
1995). The discrepancy between in vitro and in vivofollowed by deletion and anergy (Kyburz et al., 1993;
Kearney et al., 1994; Aichele et al., 1995). An intermedi- studies, i.e., that in vitro T cell responses largely depend
on costimulatory molecules or cytokines (Schwartz,ate activation signal will lead to moderate expansion,
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Experimental Procedures1992), but CD28-, B7-1, and IL-2-deficient mice can gen-
erate immune responses (Shahinian et al., 1993; Ku¨ndig
Miceet al., 1993c; Freeman et al., 1993), may readily be ex-
The generation of CD28-deficient mice by targeted gene disruption
plained by differences in the duration of antigen presen- has been described in detail previously (Shahinian et al., 1993).
tation. In vivo, CTL responses have been demonstrated Unless indicated otherwise, all mice used were H-2b/b, backcrossed
into C57BL/6 for more than 6 generations. C57BL/6 mice (Jacksonin IL-2- and CD28-deficient mice using LCMV (Ku¨ndig
Laboratories, Bar Harbor, Maine) were used as CD281/1 controls inet al., 1993c; Shahinian et al., 1993) or allo-grafts (Kawai
the experiments depicted. All experiments have also been done, atet al., 1996) as antigens, which both provide signal-1 for
least once, in CD281/2 littermate controls and comparable results
an extended period of time. In contrast, in vitro assays were obtained. The CD282/2 H-2k/k mice were obtained through
generally use inactivated antigen-presenting cells, by breeding into CBA/J mice. TCR1 CD282/2 mice were obtained
irradiation or chemically, which are present for only 1 through breeding of TCR1 mice (Pircher et al., 1990) in the C57BL/
6 background with CD282/2 mice in the C57BL/6 background. Allor 2 days. This may be the reason why in vitro allo-
experimental mice were between 8–12 weeks of age.specific or ovalbumin-specific CD282/2 T cells initially
proliferate, but cannot sustain this response (Green et
Viruses
al., 1994; Lucas et al., 1995, Kawai et al. 1996). VSV serotype Indiana was obtained from Dr. L. Prevec (McMaster
In vitro results demonstrated that high antigen density University, Hamilton, Ontario, Canada). Seeds were grown on BHK
or high concentrations of anti-CD3 antibody and there- cells and plaqued on Vero cells following standard protocols
(Wagner, 1987). LCMV (Armstrong isolate) was originally obtainedfore supraoptimal TCR signaling can replace signal-2
from Dr. M. B. A. Oldstone (Scripps Clinics and Research Founda-(Harding et al., 1992; Green et al., 1994). Although we
tion, LaJolla, San Diego, California) (Buchmeier et al., 1980). Seedsobserved no such dose effect with viral peptides in vivo
were grown on BHK cells and plaqued on MC57 cells using an
(Figure 3), this does not rule out that the dose of other immunological focus assay, as described previously (Battegay et
antigens may influence in vivo costimulatory require- al., 1991). vv–VSV–np was a gift from Dr. B. Moss (National Institutes
of Health, Bethesda, Maryland) (Mackett et al., 1985). vv–LCMV–npments. Several antigens might provide a stronger
was provided by Dr. D. H. L. Bishop (Oxford University, Oxford, Greatsignal-1 than that achieved here by exogenously loading
Britain) (Hany et al., 1989). The characterization of vv–LCMV–np hasMHC molecules. Also, since viral peptides are unstable
been previously described (Hany et al., 1989). vv–LCMV–np was
in serum, not retained by kidney membranes and there- used to present a low virulence vaccinia strain, whereas vaccinia
fore immediately excreted (Widmann et al., 1991; Ku¨ndig strain WR, from which vv–LCMV–np is derived, was used as the
et al., 1992), injection of higher doses cannot signifi- high virulence thymidine kinase–positive strain.
cantly prolong the duration of antigen presentation,
Depletion of CD41 T cellswhereas increasing doses of other antigens may cru-
The rat monoclonal antibody YTS191.1 was used for the in vivocially prolong antigen presentation.
depletion of CD41 T cells (Cobbold et al., 1984; Leist et al., 1987).
Our results do not completely follow the basic two- It was produced in rat ascites and purified as described previously
signal model of peripheral self-tolerance (Bretscher and (Cobbold et al., 1984). Mice were given 1 mg on day 23 and 1 mg
Cohn, 1970; Lafferty and Woolnough, 1977; Janeway, on day 21 before beginning the experiment. In control mice, this
treatment depleted CD41 T cells below detection levels by FCM1989), since self-antigens would always be present to
analysis when stained with GK1.5 (Dialynas et al., 1983) and com-deliver signal-1 and thus may induce an immune re-
pletely abrogated CD41 T helper cell function: after immunizationsponse. However, T cells that may have the potential to
with VSV the T helper–independent neutralizing immunoglobulin M
react with a self-antigen do not generally extravasate (IgM) response was not followed by any detectable immunoglobulin
and interact with self-ligands in a particular organ. In class switch to IgG (Leist et al., 1987).
addition, MHC expression on most tissues is relatively
In Vivo Protection Assays of CTL Activitylow, therefore limiting self-antigen presentation and
The in vivo assay for the detection of CTL activity by challengeavoiding efficient interaction with autoreactive T cells
infections with vaccinia recombinant viruses has been described in(Boehme et al., 1989; Ohashi et al., 1991, 1993; von
detail previously (Binder and Ku¨ndig, 1991). In brief, mice that had
Herrath et al., 1994; Ando et al., 1994). Under conditions been immunized with either VSV or LCMV wild type are challenged
where inflammation is induced or aberrant expression intracerebrally by infection with vaccinia recombinant viruses ex-
pressing VSV or LCMV proteins, respectively (5 3 103 pfu in 30 ml).of self-ligand presentation exists, sustained signal-1
The titers of the vaccinia recombinant virus were determined in brainthrough the TCR may provide an explanation for the
homogenates 5 days after the challenge infection, using a standarddirect induction of T cell function by nonprofessional
virus plaque assay (Karupiah et al., 1990). If VSV- or LCMV-specific
APCs. memory CTL were present, then the respective vaccinia recombi-
In conclusion, these studies using CD28-deficient nant virus is usually eliminated below detection levels at this time-
point. Conversely, if replication of the vaccinia recombinant virusesmice demonstrate that in absence of the CD28-costimu-
in the experimental animals is comparable to replication in unprimedlatory signal-2, anergy results from transmission of sig-
control mice, this indicates the functional absence of in vivo VSV-nal-1 alone, either through low virulence virus infection
or LCMV-specific CTL activity.
or injection of viral peptide. This is in accordance with
the traditional two-signal model of lymphocyte activa- Primary Ex Vivo Cytotoxicity Against VSV and LCMV
tion. In addition, the biological relevance of CD81 T cell Mice were infected intravenously with VSV (2 3 106 pfu on day 26)
or with LCMV (2 3 103 pfu on day 28) or with vaccinia virusesanergy was confirmed in vivo, by a lack of protection to
(5 3 104 pfu intravenously on day 26). On day 0, spleen cells weresubsequent viral infection. Our studies, however, modify
coincubated for 5 hr with 51Cr-labeled MC57 (H-2b) target cells thatthe two-signal model by demonstrating that the contin-
were either uninfected, or infected with VSV (15 pfu per target cell
ued presence of signal-1, either through high virulence for 2 hr), with LCMV (infection at low multiplicity of infection 48 hr
infection, or repeated infusion of peptide, generates a before assay), or with vaccinia virus (strain WR 5 pfu per target cell
for 2 hr). Specific lysis was calculated as (experimental 51Cr release 2functional T cell response.
Immunity
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spontaneous 51Cr release) / (total 51Cr release 2 spontaneous 51Cr for the assessment of T- and B-cell function. Curr. Opin. Immunol.
6, 320–326.release) 3 100%.
Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L.M., Free-
man, G.J., and Glimcher, L.H. (1994). Constitutive expression of B7LCMV-Induced Footpad Swelling Reaction
Mice were infected with LCMV Armstrong by intradermal injection restores immunogenicity of tumor cells expressing truncated MHC
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(thickness before injection). meningitis virus with an immunological focus assay in 24 or 96 well
plates. J. Virol. Meth. 33, 191–198.
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